StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Aimovig Global Growth in Constant Currencies by Year

Aimovig Global Growth in Constant Currencies (% cc) (%)

Novartis Aimovig Global Growth in Constant Currencies: 3.0% in FY2025, down 15.0 pts from a year earlier.

Latest, FY2025
3.0%
Period ended Dec 31, 2025
Change on a year earlier
-15.0 pts
18.0% in FY2024
History
5 years
Since FY2020
Sources
5
Documents cited below

Where the FY2025 figure comes from

“|| Aimovig | 335 | 312 | 7 | 3”

Source: Novartis Form 6-K (0001114448-26-000007) ↗

Reported in Form 6-K & Form 20-F.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAimovig Global Growth in Constant Currencies (% cc) (%)Year on yearSource
FY2025Dec 31, 20253.0%-15.0 ptsNovartis Form 6-K (0001114448-26-000007) ↗
FY2024Dec 31, 202418.0%-3.0 ptsNovartis Form 6-K (0001370368-25-000007) ↗
FY2023Dec 31, 202321.0%+10.0 ptsNovartis Form 6-K (0001370368-24-000007) ↗
FY2022Dec 31, 202211.0%–Novartis Form 6-K (0001370368-23-000008) ↗
FY2020Dec 31, 202057.0%–Novartis Form 6-K (0001370368-21-000008) ↗

Cite this data

StockData. (2026). Novartis Aimovig Global Growth in Constant Currencies (%), annual FY2020–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-aimovig-yoy-cc-pct

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.